+

MX2025003665A - Derivados macrociclicos y las aplicaciones de estos - Google Patents

Derivados macrociclicos y las aplicaciones de estos

Info

Publication number
MX2025003665A
MX2025003665A MX2025003665A MX2025003665A MX2025003665A MX 2025003665 A MX2025003665 A MX 2025003665A MX 2025003665 A MX2025003665 A MX 2025003665A MX 2025003665 A MX2025003665 A MX 2025003665A MX 2025003665 A MX2025003665 A MX 2025003665A
Authority
MX
Mexico
Prior art keywords
macrocyclic derivative
macrocyclic
derivative
stereoisomer
formula
Prior art date
Application number
MX2025003665A
Other languages
English (en)
Inventor
Yang Zhang
Kai Zhou
Fen Jiang
Li Zhang
Xiao Liu
Zheng Wang
CHEN Kevin X
Jian Li
Shuhui Chen
Original Assignee
Guangzhou Joyo Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Joyo Pharmatech Co Ltd filed Critical Guangzhou Joyo Pharmatech Co Ltd
Publication of MX2025003665A publication Critical patent/MX2025003665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción describe una clase de derivados macrocíclicos, y describe específicamente un compuesto que se muestra en la fórmula (VI), un estereoisómero de este, y una sal farmacéuticamente aceptable de este. (ver fórmula (VI)).
MX2025003665A 2022-09-29 2025-03-27 Derivados macrociclicos y las aplicaciones de estos MX2025003665A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202211213222 2022-09-29
CN202310132699 2023-02-17
CN202310371165 2023-04-07
CN202310685748 2023-06-09
CN202310911632 2023-07-24
PCT/CN2023/122877 WO2024067857A1 (zh) 2022-09-29 2023-09-28 大环衍生物及其应用

Publications (1)

Publication Number Publication Date
MX2025003665A true MX2025003665A (es) 2025-07-01

Family

ID=90476442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025003665A MX2025003665A (es) 2022-09-29 2025-03-27 Derivados macrociclicos y las aplicaciones de estos

Country Status (9)

Country Link
US (2) US20250205245A1 (es)
EP (1) EP4596552A1 (es)
JP (1) JP2025532258A (es)
KR (1) KR20250085767A (es)
CN (2) CN119977995A (es)
AU (1) AU2023350264A1 (es)
IL (1) IL319845A (es)
MX (1) MX2025003665A (es)
WO (1) WO2024067857A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4469164A1 (en) 2023-02-14 2024-12-04 F. Hoffmann-La Roche AG Tricyclic compounds for the treatment of cancer
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN119350232B (zh) * 2024-12-24 2025-03-25 山东佰隆医药有限公司 一种1-（3-溴吡啶-2-基）乙酮的制备方法
CN119350371A (zh) * 2024-12-25 2025-01-24 药康众拓(北京)医药科技有限公司 氘代ras抑制剂药物及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019401466B2 (en) 2018-12-21 2025-04-24 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
CA3159561A1 (en) * 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
JP2022553859A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CN116457358A (zh) * 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
WO2023015559A1 (en) * 2021-08-13 2023-02-16 Nutshell Biotech (Shanghai) Co., Ltd. Macrocycle compounds as inhibitors of ras
US20250066386A1 (en) * 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras

Also Published As

Publication number Publication date
US20250268907A1 (en) 2025-08-28
WO2024067857A1 (zh) 2024-04-04
JP2025532258A (ja) 2025-09-29
KR20250085767A (ko) 2025-06-12
AU2023350264A1 (en) 2025-04-10
US20250205245A1 (en) 2025-06-26
EP4596552A1 (en) 2025-08-06
CN119977995A (zh) 2025-05-13
CN119522225A (zh) 2025-02-25
IL319845A (en) 2025-05-01

Similar Documents

Publication Publication Date Title
MX2025003665A (es) Derivados macrociclicos y las aplicaciones de estos
PH12022552395A1 (en) Pyrimidoheterocyclic compounds and application thereof
PH12021552805A1 (en) Cdk inhibitors
EP4306111A3 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
PH12023550018A1 (en) Phthalazinone compound, and preparation method therefor and medical use thereof
MX2023009278A (es) Compuestos ciclicos aromaticos pirimidina.
ZA202308002B (en) Pyrimidopyran compound
EP4438122A3 (en) Ring-modified proline short peptide compound and use thereof
ZA202406389B (en) Benzopyrimidine compounds and use thereof
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
PH12022550832A1 (en) ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS.
ZA202208051B (en) Protein degradation agent compound preparation method and application
MX2021007140A (es) Compuesto para usarse en enfermedades de la retina.
MX2024015714A (es) Compuesto de pirimidopirano sustituido heterocíclico y uso de este
PH12021552513A1 (en) Pyrrole compounds
EP4403174A3 (en) Pyrrolo[1,2-b]pyridazine derivatives
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
MX2025001749A (es) Compuesto como inhibidor del canal de sodio dependiente del voltaje
PH12019550154A1 (en) Azetidine derivative
WO2022057836A8 (zh) 苯并脲环衍生物及其制备方法和应用
MX2024005066A (es) Compuestos de cd73.
PH12022553516A1 (en) Novel pyrazole derivatives
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载